Editorial: Repurposing cancer immunotherapies for use in autoimmunity and transplantation.
作者信息
Boardman Dominic A, Smyth Lesley A, Ferreira Leonardo M R
机构信息
Department of Surgery, The University of British Columbia, Vancouver, BC, Canada.
BC Children's Hospital Research Institute, Vancouver, BC, Canada.
出版信息
Front Immunol. 2025 Sep 1;16:1690655. doi: 10.3389/fimmu.2025.1690655. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Repurposing cancer immunotherapies for use in autoimmunity and transplantation.社论：将癌症免疫疗法重新用于自身免疫性疾病和移植领域。
Front Immunol. 2025 Sep 1;16:1690655. doi: 10.3389/fimmu.2025.1690655. eCollection 2025.
2
Current advancements in cellular immunotherapy for autoimmune disease.自身免疫性疾病细胞免疫疗法的当前进展。
Semin Immunopathol. 2025 Jan 16;47(1):7. doi: 10.1007/s00281-024-01034-5.
3
Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells.通过嵌合抗原受体调节性T细胞革新异基因移植物耐受性
Biomedicines. 2025 Jul 18;13(7):1757. doi: 10.3390/biomedicines13071757.
4
Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity.调节性 T 细胞治疗在移植和自身免疫中的过去、现在和未来。
Front Immunol. 2019 Jan 31;10:43. doi: 10.3389/fimmu.2019.00043. eCollection 2019.
5
The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases.白细胞介素-2的持久影响：迈向推进免疫耐受、癌症免疫疗法和自身免疫性疾病的50年
Immunol Invest. 2025 Jul;54(5):589-603. doi: 10.1080/08820139.2025.2479609. Epub 2025 Mar 17.
6
Effect of regulatory T cells on short-term graft outcome in kidney transplant recipients, a prospective observational, single-center study.调节性 T 细胞对肾移植受者短期移植物结局的影响：一项前瞻性观察性单中心研究。
Transpl Immunol. 2022 Aug;73:101630. doi: 10.1016/j.trim.2022.101630. Epub 2022 May 25.
7
Alterations in CD4 T-cell Subsets in Living Donor Liver Transplantation Associated With Graft Rejection.活体肝移植中与移植物排斥相关的CD4 T细胞亚群改变
J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101428. doi: 10.1016/j.jceh.2024.101428. Epub 2024 Apr 16.
8
Do CD4+ Foxp3+ Treg cells correlate with transplant outcomes: a systematic review on recipients of solid organ transplantation.CD4+Foxp3+Treg 细胞与移植结局相关吗？——实体器官移植受者的系统评价
Cell Immunol. 2011;270(1):5-12. doi: 10.1016/j.cellimm.2011.05.006. Epub 2011 May 12.
9
Repurposing Histone Deacetylase Inhibitors for Management of Solid Organ Transplant Rejection.重新利用组蛋白去乙酰化酶抑制剂治疗实体器官移植排斥反应。
Results Probl Cell Differ. 2025;75:309-328. doi: 10.1007/978-3-031-91459-1_11.
10
Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?调控免疫细胞：引入抗原特异性调节 T 细胞治疗自身免疫疾病的下一步？
Cell Immunol. 2020 Dec;358:104236. doi: 10.1016/j.cellimm.2020.104236. Epub 2020 Oct 13.
本文引用的文献
1
Harnessing the biology of regulatory T cells to treat disease.利用调节性T细胞的生物学特性治疗疾病。
Nat Rev Drug Discov. 2025 Feb;24(2):93-111. doi: 10.1038/s41573-024-01089-x. Epub 2024 Dec 16.
2
IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function.IL-6 和 TNFα 驱动人 Treg 大量增殖，而不损害其谱系稳定性或功能。
Front Immunol. 2021 Dec 23;12:783282. doi: 10.3389/fimmu.2021.783282. eCollection 2021.
3
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.调节性 T 细胞中抗 HLA-A2 嵌合抗原受体的精确工程化用于移植免疫耐受。
Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021.
4
CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII.CAR- 和 TRuC- 重定向的调节性 T 细胞在控制对 FVIII 的适应性免疫的能力上存在差异。
Mol Ther. 2021 Sep 1;29(9):2660-2676. doi: 10.1016/j.ymthe.2021.04.034. Epub 2021 May 1.
5
Next-generation regulatory T cell therapy.下一代调节性 T 细胞治疗。
Nat Rev Drug Discov. 2019 Oct;18(10):749-769. doi: 10.1038/s41573-019-0041-4. Epub 2019 Sep 20.
6
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.发现并表征 AZD6738，一种强效的共济失调毛细血管扩张突变和 Rad3 相关（ATR）激酶抑制剂，可作为抗癌药物应用。
J Med Chem. 2018 Nov 21;61(22):9889-9907. doi: 10.1021/acs.jmedchem.8b01187. Epub 2018 Nov 10.
7
Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.针对供体HLA I类的嵌合抗原受体的表达增强了人类调节性T细胞预防人类皮肤移植排斥反应的能力。
Am J Transplant. 2017 Apr;17(4):931-943. doi: 10.1111/ajt.14185. Epub 2017 Feb 1.
8
Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor.使用具有MHC特异性嵌合抗原受体的调节性T细胞预防同种异体移植排斥反应
Am J Transplant. 2017 Apr;17(4):917-930. doi: 10.1111/ajt.14175. Epub 2017 Feb 6.
9
Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.通过嵌合抗原受体产生的同种异体抗原特异性调节性T细胞。
J Clin Invest. 2016 Apr 1;126(4):1413-24. doi: 10.1172/JCI82771. Epub 2016 Mar 21.
10
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.磷酸肌醇-3-激酶（PI3K）-δ和γ抑制剂IPI-145（度维利塞）可克服PI3K/AKT/S6信号通路的信号，并促进慢性淋巴细胞白血病（CLL）细胞凋亡。
Leukemia. 2015 Sep;29(9):1811-22. doi: 10.1038/leu.2015.105. Epub 2015 Apr 28.
Zotero 插件